Patients with Type 2 diabetes have an elevated risk of stroke. The role of lipid levels and diabetes-specific factors in risk prediction of stroke is unclear, and estimates of efficacy of lipid-lowering therapy vary between trials. We examined predictors of stroke and the effect of atorvastatin on specific stroke subtypes in Type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS) [a trial of 2838 participants with mean low-density lipoprotein cholesterol <4.14 mmol/l, no history of macrovascular disease and randomized to atorvastatin 10 mg daily or placebo].
Hitman, G. A., Colhoun, H., Newman, C., Szarek, M., Betteridge, D. J., Durrington, P. N., Fuller, J., Livingstone, S., Neil, H. A. W., & CARDS Investigators (2007). Stroke prediction and stroke prevention with atorvastatin in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetic Medicine, 24(12), 1313-1321. https://doi.org/10.1111/j.1464-5491.2007.02268.x